Korro Bio, Inc. (KRRO) Stock Grade

About Korro Bio, Inc.'s fundamentals

Korro Bio is a clinical-stage biotechnology company with a market capitalization of $75.3 million that reported exceptional revenue growth of 181.5% year-over-year, though from a relatively small base typical of early-stage biotech firms. The company currently operates at a significant loss, with a net margin of -1834.5%, and reported a net loss in its latest annual statement, which is common for companies in early development stages that are investing heavily in research and development. The company does not pay a dividend, and profitability metrics like P/E ratio and return on equity are not applicable given the loss-making status. Investors should note that the company's financial structure reflects the high-risk, high-investment nature of biotechnology development.